-
Benralizumab, sold
under the
brand name Fasenra, is a
monoclonal antibody directed against the
alpha chain of the interleukin-5
receptor (CD125). It was...
-
mepolizumab or
reslizumab against IL-5,
prevents eosinophilopoiesis, or
benralizumab against IL-5 receptor,
which eliminates eosinophils through ADCC antagonists...
-
Acalabrutinib Anastrozole Andexanet alfa
Anifrolumab Asfotase alfa
Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide Budesonide/formoterol Budesonide/glycopyrronium...
- drug is a
human monoclonal antibody acting against tumors. The name of
benralizumab, a drug
designed for the
treatment of asthma, has the
components benra-li-zu-mab...
- On 18
September 2024,
AstraZeneca announced FDA
approval for
Fasenra (
benralizumab), a
biologic drug
therapy indicated for use in
adult patients with EGPA...
-
asthma symptomatic control include omalizumab, mepolizumab, reslizumab,
benralizumab,
dupilumab and tezepelumab.
Omalizumab binds to free
human immunoglobulin...
- (anti-PD-L1)
tremelimumab (anti-CTLA-4)
moxetumomab pasudotox (anti-CD22)
benralizumab (anti-IL-5R)
tralokinumab (anti-IL-13)
anifrolumab (anti-IFN-aR) nirsevimab...
- symptoms. Some
examples of
these drugs include mepolizumab, reslizumab, and
benralizumab.
Although eosinopenia has long been
recognized as a
laboratory marker...
-
Acalabrutinib Anastrozole Andexanet alfa
Anifrolumab Asfotase alfa
Atenolol Benralizumab Bicalutamide Brompheniramine Budesonide Budesonide/formoterol Budesonide/glycopyrronium...
- (IL-5) or its
receptor (IL-5R),
including mepolizumab,
reslizumab or
benralizumab, in
addition to
standard care in
severe asthma is
effective in reducing...
